Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01731665|
Recruitment Status : Recruiting
First Posted : November 22, 2012
Last Update Posted : July 12, 2016
|Condition or disease|
|Crohn's Disease Ulcerative Colitis Epidemiology Korea|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||June 2018|
The Songpa-Kangdong cohort of IBD
Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
- Incidence rate and prevalence rate of IBD [ Time Frame: 1986-2017 (up to 31 years) ]
- Annual incidence rate of Crohn's disease and ulcerative colitis
- Prevalence rate of Crohn's disease and ulcerative colitis as of Dec 31, 2017.
- Clinical features of patients with IBD [ Time Frame: 1986-2017 (up to 31 years) ]
- Clinical characteristics of patients newly diagnosed with Crohn's disease or ulcerative colitis: gender, presenting symptoms, duration between symptoms to diagnosis, and phenotypes, etc.
- Clinical course of patients newly diagnosed with Crohn's disease or ulcerative colitis: development of complications (strictures, perforations), intestinal resection rate, hospitalization rate, mortality, and pregnancies and their outcomes
- Treatment modalities of IBD and their trends: use of medication (5-ASA, corticosteroids, immunomodulators, and biologic agents, etc.)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01731665
|Contact: Suk-Kyun Yang, M.D.||+email@example.com|
|Contact: Byong Duk Ye, M.D.||+firstname.lastname@example.org|
|Korea, Republic of|
|Asan Medical Center||Recruiting|
|Seoul, Korea, Republic of, 138-736|
|Contact: Suk-Kyun Yang, M.D. +82-2-3010-3901 email@example.com|
|Contact: Byong Duk Ye, M.D. +82-2-3010-3181 firstname.lastname@example.org|
|Principal Investigator: Suk-Kyun Yang, M.D.|
|Principal Investigator:||Suk-Kyun Yang, M.D.||Asan Medical Center|